Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Peramivir's Influenza Trial Results Promising, but Report Lacks Clarity

July 19, 2009

Analysis of:BioCryst's influenza drug shows promise in study | www.reuters.com

The Biocryst influenza drug, Peramivir, shows promise in recent report. The drug, like Tamiflu, appears safe and, when used in a single intravenous injection, had efficacy vs influenza similar to orally administered Tamiflu. The injection route, requiring administration by medical personnel, should allow approval by regulatory agencies. The report, however, lacked important detail regarding actual efficacy seen and time of treatment relative to symptoms, so complete analysis is difficult.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS